Servings Per Container: 60 vegetarian capsules 500 mg. each

Ingredients: Per Serving (one capusle) -A proprietary blend of Terminalia Arjuna, Inula Racemoses, Guggul, Garlic, CoQ10, Magnesium, Bioperine.

Recommended Dosage : 1 capsule twice daily

Indications:

Tattva's Herbs' Cardiac Support formula combines the poweful Ayurvedic cardiotonic herbals, Arjuna, Inula Racemosa, and Guggul, with the potent antioxidant properties of CoQ10. According to clinical studies, Arjuna has been shown to reduce the existence of angina attacks in persons with pre-existing angina. It has also demonstrated the power to alleviate artheriosclerosis, improve conditions in congestive heart failure patients and lower blood pressure in hypertensive patients. CoQ10 is a critical nutrient involved with producing energy within our bodies' cells. Studies of CoQ10s' clinical value has demonstrated its significance in treating heart disease, increasing energy and enhancing the immune system. This proprietary Ayurvedic Formula helps to improve all heart functions, reduce the deposit of cholesterol in the arteries, and assist in controlling high blood pressure.

Cardiovascular System

Arjuna reduces the incidence of Angina attacks in persons with pre-existing Angina (by approximately 50%). peer-reviewed research - See Below
Arjuna alleviates Atherosclerosis. research See Below
Arjuna improves the condition of (chronic) Congestive Heart Failure patients. peer-reviewed research See Below

Arjun lowers Blood Pressure in Hypertension patients. research

Research

Dwivedi, S., et al. Antianginal and cardioprotective effects of Terminalia arjuna, an indigenous drug, in coronary artery disease. J Assoc Physicans India. 42:287-289, 1994.

Arjuna was found to be effective for patients with stable angina, causing a 50% reduction in angina episodes and a significant decrease in systolic blood pressure.

An open study of Terminalia's effects on stable and unstable angina revealed a 50% reduction of anginal episodes in patients with stable angina (p < 0.01) after three months. A statistically significant reduction was also noted in systolic blood pressure in these patients (p < 0.05). On treadmill testing, both the time to onset of angina and the time to appearance of ECG ST-T changes were significantly increased in the stable angina group (p < 0.001), indicating an improvement in exercise tolerance. The unstable angina patients in this study did not experience significant reductions in angina or systolic blood pressure. Both groups showed improvements in left ventricular ejection fraction. When these improvements were combined for statistical purposes, the improvements were significant (p < 0.05). Evaluating the overall clinical condition, treadmill testing, and ejection fraction, 66% of the stable angina patients and 20% of the unstable angina patients improved during three months of therapy.

· Dwivedi, S., et al. Beneficial effects of Terminalia arjuna in coronary artery disease. Indian Heart J. 49:507-510, 1997.

· Miller, A. L. Botanical influences on cardiovascular disease. Alternative Medicine Review. 3(6):422-431, 1998.

· Ram, A., et al. Hypocholesterolaemic effects of Terminalia arjuna tree bark. Journal of Ethnopharmacology. 55:165-169, 1997.

Rabbits were made hyperlipidemic by feeding them an atherogenic diet. Two groups were given a Terminalia extract orally, and one group was used as a placebo control group. The animals given Terminalia had a significant, dose-related decrease in total and LDL cholesterol, compared to placebo (p < 0.01). However, the amounts used (100 mg/kg and 500 mg/kg body weight) were very large, and it remains to be seen if these significant changes will be seen in humans taking relatively smaller oral doses.

· Khosh, F. Natural approach to hypertension. Alternative Medicine Review. 6(6), 2001.

· Miller, A. L. Botanical influences on cardiovascular disease. Alternative Medicine Review. 3(6):422-431, 1998.

Bharani, A., et al. Salutary effect of Terminalia arjuna in patients with severe refractory heart failure. Int J Cardiol. 49:191-199, 1995.

In this double-blind, crossover study, 12 subjects with refractory chronic congestive heart failiure (idiopathic dilated cardiomyopathy - 10 patients, previous heart attack - 1 patient, peripartum cardiomyopathy - 1 patient) received Terminalia arjuna bark extract (500 mg every eight hours, or placebo, for two weeks, each treatment separated by a two-week washout period), as an adjuvant to conventional therapy. Clinical, laboratory, and echocardiographic evaluations were carried out at baseline and at the end of the therapy. Terminalia, compared to placebo, was associated with improvement in symptoms and signs of heart failure, decrease in echo-left vendricular end diastolic and end systolic volume indices, increase in left ventricular stroke volume index, and increase in left ventricular ejection fractions. Walking distance improved in patients receiving Terminalia arjuna. In the second phase of the study, patients from phase I were continued on Terminalia extract for approximately two years. Improvements were noted in the ensuing two to three months, and were maintained throughout the balance of the study. After four months of treatment, nine patients had improved to NYHA Class II and three improved to Class III. This was a significant piece of research, as these patients had not responded to conventional drug therapy, and yet had significant improvements in objective and subjective parameters while receiving arjun.